Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
5.29
Dollar change
0.00
Percentage change
0.00
%
IndexRUT P/E- EPS (ttm)-6.38 Insider Own5.77% Shs Outstand118.79M Perf Week23.02%
Market Cap628.40M Forward P/E- EPS next Y-0.39 Insider Trans0.00% Shs Float111.93M Perf Month30.62%
Income-548.92M PEG- EPS next Q-0.45 Inst Own66.85% Short Float46.54% Perf Quarter-1.12%
Sales1.05B P/S0.60 EPS this Y49.86% Inst Trans3.80% Short Ratio6.22 Perf Half Y-41.29%
Book/sh-5.71 P/B- EPS next Y90.71% ROA-27.97% Short Interest52.09M Perf Year-41.87%
Cash/sh5.57 P/C0.95 EPS next 5Y- ROE- 52W Range3.53 - 11.36 Perf YTD10.21%
Dividend Est.- P/FCF- EPS past 5Y7.76% ROI- 52W High-53.43% Beta1.60
Dividend TTM- Quick Ratio0.64 Sales past 5Y654.21% Gross Margin65.94% 52W Low49.76% ATR (14)0.36
Dividend Ex-Date- Current Ratio0.69 EPS Y/Y TTM63.34% Oper. Margin-58.32% RSI (14)67.94 Volatility10.41% 7.25%
Employees1992 Debt/Eq- Sales Y/Y TTM-43.15% Profit Margin-52.29% Recom2.50 Target Price19.20
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q41.30% Payout- Rel Volume0.00 Prev Close5.29
Sales Surprise62.00% EPS Surprise43.12% Sales Q/Q-74.55% EarningsFeb 28 BMO Avg Volume8.37M Price5.29
SMA2028.38% SMA5016.78% SMA200-20.63% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Aug-09-23Upgrade B. Riley Securities Neutral → Buy $15
Apr-20-23Downgrade TD Cowen Outperform → Market Perform $55 → $10
Mar-01-23Downgrade B. Riley Securities Buy → Neutral $29 → $10
Jan-09-23Reiterated B. Riley Securities Buy $74 → $37
Dec-30-22Reiterated H.C. Wainwright Buy $207 → $110
Dec-02-22Initiated Jefferies Hold
Sep-22-22Downgrade JP Morgan Neutral → Underweight $132 → $27
May-20-22Initiated BofA Securities Underperform $35
Feb-23-22Reiterated B. Riley Securities Buy $315 → $265
Feb-22-22Resumed Jefferies Buy $198
Today 02:46AM
Feb-23-24 07:35AM
Feb-22-24 03:52PM
01:39PM
12:39PM
11:09AM Loading…
11:09AM
09:47AM
06:21AM
06:10AM
06:00AM
06:00AM
Feb-20-24 10:00AM
09:25AM
Feb-15-24 04:01PM
05:17AM
05:00PM Loading…
Feb-11-24 05:00PM
Feb-05-24 09:20AM
Feb-03-24 08:07PM
05:35AM
Feb-01-24 05:04AM
Jan-31-24 01:33PM
11:17AM
08:22AM
08:15AM
08:08AM
05:06AM
Jan-29-24 08:15AM
Jan-28-24 07:25AM
03:15AM
Jan-27-24 08:45AM
11:34AM Loading…
Jan-25-24 11:34AM
Jan-23-24 09:13AM
Jan-15-24 04:05PM
02:21PM
Jan-10-24 07:35AM
Jan-09-24 05:21AM
Jan-03-24 09:25AM
Jan-02-24 05:06AM
Dec-28-23 06:45AM
Dec-25-23 05:23AM
Dec-20-23 11:02AM
Dec-18-23 08:00AM
12:55AM
Dec-14-23 02:10PM
Dec-13-23 08:00AM
Dec-05-23 04:40PM
04:07PM
04:01PM
Dec-01-23 04:00PM
Nov-30-23 12:16PM
07:00AM
Nov-29-23 11:53AM
Nov-28-23 06:28AM
06:07AM
06:00AM
Nov-22-23 10:44AM
Nov-17-23 07:15AM
Nov-15-23 05:20AM
Nov-11-23 05:30AM
Nov-10-23 01:28PM
09:25AM
09:06AM
Nov-09-23 11:28AM
10:57AM
09:40AM
08:22AM
08:06AM
08:00AM
07:52AM
01:00AM
Nov-02-23 10:00AM
09:25AM
Nov-01-23 03:10PM
10:43AM
Oct-31-23 04:37PM
12:58PM
Oct-18-23 08:05AM
08:00AM
Oct-17-23 10:17AM
06:00AM
Oct-16-23 04:07PM
03:34PM
08:01AM
07:13AM
06:34AM
Oct-15-23 12:57AM
12:21AM
12:00AM
Oct-13-23 01:38PM
09:47AM
09:31AM
09:29AM
Oct-12-23 06:00AM
Oct-11-23 08:00AM
Oct-10-23 12:04PM
09:06AM
Oct-09-23 12:25PM
12:01PM
Oct-07-23 05:30AM
Oct-06-23 06:00AM
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dubovsky FilipPresident, R&DDec 14Option Exercise5.692,83316,12055,150Dec 18 05:00 PM
Dubovsky FilipPresident, R&DNov 05Option Exercise7.061,4009,88452,994Nov 07 05:30 PM
Dubovsky FilipPresident, R&DSep 16Option Exercise7.7112,64497,48557,702Sep 19 05:16 PM
Dubovsky FilipPresident, R&DJun 16Option Exercise8.044,15533,40647,065Jun 21 04:40 PM
Glenn Gregory MPresident, R&DMar 10Option Exercise6.526,29841,06320,771Mar 14 05:16 PM
Trizzino JohnEVP, CCO and CBOMar 10Option Exercise6.524,60930,05111,531Mar 14 05:20 PM
Kelly James PatrickEVP, CFO and TreasurerMar 10Option Exercise6.524,60930,0515,832Mar 14 05:19 PM
Herrmann John A IIIEVP, Chief Legal OfficerMar 10Option Exercise6.524,60930,05113,058Mar 14 05:18 PM
Glenn Gregory MPresident, R&DMar 10Buy6.501,0006,50014,473Mar 14 05:16 PM
Glenn Gregory MPresident, R&DMar 07Buy7.042,00014,08813,473Mar 14 05:16 PM
Glenn Gregory MPresident, R&DMar 06Buy7.483,00022,45411,473Mar 14 05:16 PM